Clinical Report

Undetectable serum calcidiol: not everything that glitters is gold

Gioconda Gallegos-Bayas, José Francisco Pascual-Pareja, Maria D. Sanchez-Niño, Felix Manzarbeitia and Alberto Ortiz

Department of Family and Community Medicine, Centro de Salud Barrio del Pilar, Area 5, Madrid, Spain, Department of Internal Medicine, Hospital Cantoblanco-La Paz, Universidad Autonoma de Madrid, Madrid, (IdiPAZ), Spain, Department of Nephrology, IIS-Fundacion Jimenez Diaz, Universidad Autonoma de Madrid, Madrid, Spain and Department of Pathology, IIS-Fundacion Jimenez Diaz, Universidad Autonoma de Madrid, Madrid, Spain

Correspondence and offprint requests to: Alberto Ortiz; E-mail: Aortiz@fjd.es

Abstract

There is an increased awareness of the adverse consequences of nutritional vitamin D deficiency. We report a patient with chronic tophaceous gout, chronic kidney disease (CKD) Stage 3/4 and undetectable serum calcidiol who developed severe hypercalcaemia upon vitamin D supplementation despite serum 25(OH) vitamin D within the normal range. Upon recovery, serum 1,25(OH)2 vitamin D remained in the normal range despite CKD and serum 25(OH) vitamin D 6 ng/mL. Gout tophi biopsies from additional patients showed macrophage expression of 25(OH) vitamin D 1α-hydroxylase. This case illustrates the dangers of supplementing vitamin D in patients with low serum 25(OH) vitamin D and increased 1α-hydroxylase activity due to granulomatous disease.

Keywords: 25-hydroxyvitamin D-1α-hydroxylase; 1,25(OH)2 vitamin D; CYP24; chronic tophaceous gout; vitamin D deficiency

Background

Increased awareness of the adverse consequences of nutritional vitamin D deficiency has led to guideline recommendations on monitoring serum 25(OH) vitamin D and correction of any deficiency [1]. We report a case in which correction of vitamin D deficiency led to hypercalcaemia in a patient with granulomatous disease caused by chronic tophaceous gout.

Case report

A 75-year-old male was admitted for constitutional syndrome, nausea, diarrhoea and vomiting. He had hypertension, chronic kidney disease (CKD) Stage 3/4 (estimated glomerular filtration rate 26–32 mL/min/1.73 m2) and chronic tophaceous gout. Prescribed treatment included colchicine 2 mg q.d, allopurinol 200 mg q.d., sodium bicarbonate 2 g q.d. and weekly calcifediol (25 OHD3: 266 mcg = 16 000 U). Calcifediol was prescribed 2 months before admission due to undetectable serum 25(OH) vitamin D levels, following guidelines by the Spanish Society of Nephrology [2]. At the time of calcifediol prescription, Intact parathyroid hormone (iPTH) was 98 ng/L and total serum calcium (Ca) 2.22 mmol/L (8.9 mg/dL) [ionized Ca 1.15 mmol/L (4.6 mg/dL)].

Physical findings included disorientation and extensive, severe tophi in hands, elbows, arms, thighs and gluteus (Figure 1A and B). Key analytical values were normocytic normochromic anaemia, serum creatinine (sCr) 185 μmol/L (2.1 mg/dL), uric acid 618 μmol/L (10.4 mg/dL), calcium 3.5 mmol/L (14 mg/dL) [ionized Ca 1.87 mmol/L (7.52 mg/dL)], iPTH <3 ng/L, 25(OH) vitamin D 187 nmol/L (75 ng/mL) [normal range 37–250 nmol/L (15–100 ng/mL)], angiotensin-converting enzyme (ACE) 110.4 U/L (normal range 20–60), normal thyroid hormones and absence of anti-nuclear antibodies. There was no evidence of cancer in serum tumour markers, proteinogram, axillary lymph node biopsy, gastroscopy, colonoscopy, bone marrow biopsy, abdominal sonography, bone gammagraphy and neck, thorax, abdomen and pelvis CT scan. The CT scan showed vascular enhancement in the subcutaneous tissue in both buttocks (Figure 1C). Fine needle aspiration biopsy of the buttock lesions showed uric acid crystals.

Initial treatment at the emergency room included intravenous alendronate and fluids for suspected neoplastic hypercalcaemia. Calcifediol was stopped. Calcemia was corrected within days. Four weeks later analytical values were Ca 2.52 mmol/L (10.1 mg/dL), uric acid 618 μmol/L (10.4 mg/dL). With the diagnosis of granulomatous disease-related hypercalcaemia, the allopurinol dose was increased and prednisone 10 mg q.d. was prescribed for 1 months. At last follow-up, 10 weeks after admission, he was asymptomatic, sCr 168 μmol/L (1.9 mg/dL), Ca 2.12 mmol/L (8.5 mg/dL), P 1.07 mmol/L (3.3 mg/dL), uric acid 398 μmol/L (6.7 mg/dL), PTH 63 gg/L, 25(OH) vitamin D 15 nmol/L.
and 1,25(OH)₂ vitamin D 114 pmol/L (44 pg/mL) [normal 65–172 pmol/L (25–66 pg/mL)]. The size of gluteal lesions had decreased.

Additional studies

Based on the presence of a chronic granulomatous disease, increased ACE levels [3], hypercalcaemia despite normal 25(OH) vitamin D levels and, later in the disease, normal 1,25(OH)₂ vitamin D deficiency, it was hypothesized that the patient had increased extrarenal 1α-hydroxylase activity. However, there were no prior reports of 1α-hydroxylase expression in tophi. Thus, we performed immunohistochemistry for 1α-hydroxylase in biopsies from three additional tophaceous gout patients, which showed intense 1α-hydroxylase expression by macrophages and multinucleated cells surrounding tophi (Figure 2B). Furthermore, these cells stained for 24-hydroxylase (Figure 2C) and were confirmed to be CD68-positive macrophages (Figure 2D).

Discussion

Hypercalcaemia associated to granulomatous diseases is due to increased 25(OH) vitamin D to 1,25(OH)₂ vitamin D extrarenal conversion by activated macrophages from granulomas. Over 30 diseases have been associated with 1,25(OH)₂ vitamin D excess [4–6]. Tophaceous gout is characterized by foreign body granulomas formed by mononuclear and multinuclear macrophages surrounding microcrystal deposits of monosodic urate. Nevertheless, only one case of symptomatic hypercalcaemia related to chronic tophaceous gout has been described and this entity is not usually thought of as a cause of hypercalcaemia [7].

Granulomatous chronic tophaceous gout is the most plausible reason for the severe hypercalcaemia in our patient. We hypothesize that high doses of vitamin D supplements in the context of granulomatous disease facilitated hypercalcaemia. Granulomatous hypercalcaemia is particularly sensitive to vitamin D administration even though toxic 25(OH) vitamin D levels are not reached [5]. This has been attributed to avid 25(OH) vitamin D metabolism into 1,25(OH)₂ vitamin D by macrophage 1α-hydroxylase. Availability of 25(OH) vitamin D becomes the main regulator of 1,25(OH)₂ vitamin D synthesis. Under these circumstances, treatment of vitamin D deficiency will increase the availability of 25(OH) vitamin D and lead to high 1,25(OH)₂ vitamin D levels and hypercalcaemia [8, 9]. In our patient extensive subcutaneous tophi, evidenced in the CT scan and confirmed by fine needle aspiration biopsy, would behave as a granulomatous disease. Indeed, gout tophi were observed as hypervascularized masses through magnetic resonance or CT scans. Unfortunately 1,25(OH)₂ vitamin D levels were not verified at admission.

In normal subjects, 25(OH) vitamin D is synthesized in the liver and is converted to 1,25(OH)₂ vitamin D by kidney proximal tubular 1α-hydroxylase. CKD patients have 1,25(OH)₂ vitamin D deficiency due to loss of renal mass and negative regulation of 1α-hydroxylase by fibroblast growth factor 23. Activated macrophages in granuloma express 1α-hydroxylase and synthesize 1,25(OH)₂ vitamin D. Contrary to the tubular cell enzyme, granulomatous macrophages 1α-hydroxylase is not under the regulation of PTH or hypercalcaemia and may lead to inappropriate high 1,25(OH)₂ vitamin D levels. Abnormal 1,25(OH)₂ vitamin D synthesis is present even in normocalcaemic and normocalciuric patients with granulomatosis [5]. However, hypercalcaemia is not frequent in granulomatous diseases (20% in sarcoidosis).

In gout, there are apparently two opposing forces regulating serum 1,25(OH)₂ vitamin D at the level of renal and...
On one hand, urate may directly inhibit renal 1α-hydroxylase activity [10]. Probably as a result, serum 1,25(OH)2 vitamin D was significantly lower in patients with gout compared with controls, whereas no differences were observed for serum 25(OH) vitamin D and allopurinol did not change serum 25(OH) vitamin D levels but decreased plasma uric acid and increased 1,25(OH)2 vitamin D [11]. On the other hand, synthesis of 1,25(OH)2 vitamin D from 25(OH) vitamin D was shown in cells from knee joint synovial fluid in gout [12]. We have now observed that tophi macrophage expresses 1α-hydroxylase. This supports the notion that extensive tophi may lead to excess 1,25(OH)2 vitamin D and hypercalcaemia. 1,25(OH)2 vitamin D promotes its own catabolism by inducing the transcription of the CYP24A1 gene encoding the vitamin D catabolizing enzyme 24-hydroxylase. This mechanism is also active in macrophages and tophi macrophages expressed 24-hydroxylase. However, in macrophages, an alternative splicing yields a 24-hydroxylase protein that binds to vitamin D but does not promote its 24-hydroxylation due to a defect in mitochondrial targeting [13]. Additionally, CKD either through difficulty in excreting calcium or through loss of renal 24-hydroxylase deficiency secondary to loss of renal mass may have contributed to the severity of the manifestations.

In summary, despite the clinical guidelines recommendation to treat 25(OH) vitamin D deficiency, caution should be exercised when treating patients with granulomatous diseases, where increased 1α-hydroxylase activity could be contributing to decreased 25(OH) vitamin D levels. These patients may be at increased risk of vitamin D intoxication, even with serum 25(OH) vitamin D levels within the normal range.

Supplementary data

Colour versions of figures are available as supplementary material online. Supplementary data are available online at http://ckj.oxfordjournals.org.
Acknowledgements. Grant support: FIS PS09/00447, Sociedad Española de Nefrología, Fundacion Renal Inigo Alvarez de Toledo, ISCIII-RETIC REDinREN/RD06/0016, Programa Intensificacion Actividad. Investigadora (ISCIII/Agencia Lain-Entralgo/CM) to A.O. and FIS to M.D.S.N. We thank Susana Carrasco for technical help.

Conflict of interest statement. None declared.

References

1. Rojas-Rivera J, De La Piedra C, Ramos A et al. The expanding spectrum of biological actions of vitamin D. Nephrol Dial Transplant 2010; 25: 2850–2865
2. Torregrosa JV, Cannata Andia J, Bover J et al. [SEN Guidelines. Recommendations of the Spanish Society of Nephrology for managing bone-mineral metabolic alterations in chronic renal disease patients]. Nefrologia 2008; 28 (Suppl 1): 1–22
3. Bénétteau-Burnat B, Baudin B. Angiotensin-converting enzyme: clinical applications and laboratory investigations on serum and other biological fluids. Crit Rev Clin Lab Sci 1991; 28: 337–356
4. Jacobs TP, Bilezikian JP. Review: rare causes of hypercalcemia. J Clin Endocrinol Metab. 2005; 90: 6316–6322
5. Sharma OP. Hypercalcemia in granulomatous disorders: a clinical review. Curr Opin Pulm Med 2000; 6: 442–447
6. Kallas M, Green F, Hewison M et al. Rare causes of calcitriol-mediated hypercalcemia: a case report and literature review. J Clin Endocrinol Metab 2010; 95: 3111–3117
7. Sachdeva A, Goekeritz BE, Oliver AM. Symptomatic hypercalcemia in a patient with chronic tophaceous gout: a case report. Cases J 2008; 1: 72
8. Boon ES, Cozijn D, Brambacher PJ. Enhanced production of calcitriol, and hypercalcemia in a patient with sarcoidosis provoked by daily intake of calcioi. Eur J Clin Chem Clin Biochem 1993; 31: 679–681
9. Sandler LM, Winearls CG, Fraher LJ et al. Studies of the hypercalcemia of sarcoidosis: effect of steroids and exogenous vitamin D3 on the circulating concentrations of 1,25-dihydroxy vitamin D3. Q J Med 1984; 53: 165–180
10. Hsu CH, Patel SR, Young EW et al. Effects of purine derivatives on calcitriol metabolism in rats. Am J Physiol 1991; 260: F596–F601
11. Vanholder R, Patel S, Hsu CH. Effect of uric acid on plasma levels of 1,25(OH)2D in renal failure. J Am Soc Nephrol 1993; 4: 1035–1038
12. Hayes ME, Denton J, Freemont AJ et al. Synthesis of the active metabolite of vitamin D, 1,25(OH)2D3, by synovial fluid macrophages in arthritic diseases. Ann Rheum Dis 1989; 48: 723–729
13. Ren S, Nguyen L, Wu S et al. Alternative splicing of vitamin D-24-hydroxylase: a novel mechanism for the regulation of extrarenal 1,25-dihydroxyvitamin D synthesis. J Biol Chem 2005; 280: 20604–20611

Received for publication: 1.3.11; Accepted in revised form: 26.8.11